Suchergebnisse - "Boccadoro, Mario"

PubPharm (527)

1

Predictors of early morbidity and mortality in newly diagnosed multiple myeloma : data from five randomized, controlled, phase III trials in 3700 patients

enthalten in: Leukemia | 2024

von Mai, E. | Hielscher, T. | Bertsch, U. | +26

2

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

enthalten in: The New England journal of medicine | 2024

von Sonneveld, P. | Dimopoulos, M. | Boccadoro, M. | +141

3

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma

enthalten in: bioRxiv.org | 2023

von Ziccheddu, B. | Giannotta, C. | D’Agostino, M. | +15

4

Genomic and immune determinants of resistance to anti-CD38 monoclonal antibody-based therapy in relapsed refractory multiple myeloma

enthalten in: medRxiv : the preprint server for health sciences | 2023

von Ziccheddu, B. | Giannotta, C. | D'Agostino, M. | +15

5

A prospective, multicenter study on hematopoietic stem-cell mobilization with cyclophosphamide plus granulocyte colony-stimulating factor and 'on-demand' plerixafor in multiple myeloma patients treated with novel agents

enthalten in: Haematologica | 2023

von Mina, R. | Petrucci, M. | Bonello, F. | +23

6

Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129) : final analysis of a non-randomised, multicentre, phase 2 study

enthalten in: The Lancet. Oncology | 2023

von van de Donk, N. | Minnema, M. | van der Holt, B. | +25

7

Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO) : extended follow up of an open-label, randomised, multicentre, phase 3 trial

enthalten in: The Lancet. Haematology | 2023

von Dimopoulos, M. | Terpos, E. | Boccadoro, M. | +18

8

Prospective evaluation of minimal residual disease in the phase II FORTE trial : a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing

enthalten in: EClinicalMedicine | 2023

von Oliva, S. | Genuardi, E. | Paris, L. | +22

9

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial

enthalten in: EClinicalMedicine | 2023

von Zamagni, E. | Oliva, S. | Gay, F. | +28

10

Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma : a consensus report of the European Myeloma Network

enthalten in: The Lancet. Oncology | 2023

von Ludwig, H. | Terpos, E. | van de Donk, N. | +26

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[53]